Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JGA to Demand Fixed Sum Price Adjustment Range for Low-Priced Generics
January 26, 2009
- Kaken: Hand-Sized Seprafilm
January 26, 2009
- Cravit to See NHI Price Listing for 41 Generics from 32 Companies
January 26, 2009
- Endometrial Ablation Using Microwaves Approved as Advanced Therapy
January 26, 2009
- Generics Account for 18% of Drug Cost at a Yokohama Hospital
January 26, 2009
- SELF-MEDICATION NEWS IN BRIEF
January 26, 2009
- Review of Febuxostat by FDA to Be Extended
January 26, 2009
- Revised Version of Hypertension Treatment GL Issued
January 26, 2009
- 2 Anti-HIV Drugs Included in NHI Drug Price List
January 26, 2009
- Draft GL on Peritoneal Dialysis Published: JSDT
January 26, 2009
- JPA to Watch Development in Niigata Prefecture
January 19, 2009
- Consider Expansion of Application of DRG/PPS: Council
January 19, 2009
- Create Market That Encourages Innovation: Mr Iwai of OPIR
January 19, 2009
- Give Patents to New Therapeutic Methods
January 19, 2009
- BUSINESS NEWS IN BRIEF
January 19, 2009
- Data on Tamiflu Should Be Published: Medwatcher Japan
January 19, 2009
- Sanjou General Hospital to Switch to In-House Prescriptions
January 19, 2009
- Council Chairman Proposes Reform of Vaccine Administration
January 19, 2009
- REGULATORY NEWS IN BRIEF
January 19, 2009
- SymBio Begins PI Trial of Bendamustine for New Indication
January 19, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…